KRISHAN Cheyenne/MSF
Since May 2014, Epicentre is rolling out clinical trials about a new vaccine against Rotavirus. This new vaccine manufactured by Serum Institute of India has multiple advantages: thermostability, cheaper price than the existing vaccines, less packaging needs. If proven safe and effective, this new vaccine could be a game changer especially for the children in Sub Saharan countries. In Maradi region, 7700 children have been included in this phase III clinical trials.